Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
D000008:Abdominal Neoplasms / Q000188:drug therapy; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D007223:Infant; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000652:urine; D013899:Thoracic Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014642:Vanilmandelic Acid / Q000652:urine; D014750:Vincristine / Q000627:therapeutic use*
D003609:Dactinomycin; D014642:Vanilmandelic Acid; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D003630:Daunorubicin